Anonymous
Not logged in
Talk
Contributions
Create account
Log in
Search
Editing
William Mitchell
(section)
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Namespaces
Page
Discussion
More
More
Page actions
Read
Edit
Edit source
History
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
==Notable studies== *1995, Long Term Improvements in Patients with [[Chronic Fatigue Syndrome]] Treated with [[Ampligen]]<ref name="Strayer,1995"/> [https://scholars.opb.msu.edu/en/publications/long-term-improvements-in-patients-with-chronic-fatigue-syndrome- (Abstract)] *2007, Cross-Protection against H5N1 Influenza Virus Infection Is Afforded by Intranasal Inoculation with Seasonal Trivalent Inactivated Influenza Vaccine<ref> Takeshi Ichinohe, Shin-ichi Tamura, Akira Kawaguchi, Ai Ninomiya, Masaki Imai, Shigeyuki Itamura, Takato Odagiri, Masato Tashiro, Hidehiro Takahashi, Hirofumi Sawa, William M. Mitchell, David R. Strayer, William A. Carter, Joe Chiba, Takeshi Kurata, Tetsutaro Sata and Hideki Hasegawa. The Journal of Infectious Diseases, Vol. 196, No. 9 (Nov. 1, 2007), pp. 1313-1320. Url: http://www.jstor.org/stable/30086851</ref> *2012, A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist [[rintatolimod]] in severe cases of [[chronic fatigue syndrome]]<ref name="Strayer, 2012"/> *2015, Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME): Characteristics of Responders to [[Rintatolimod]]<ref name="Strayer, 2015"/> *2016, William M. Mitchell published a review in the journal, ''Expert Review of Clinical Pharmacology'' that stated: "Rintatolimod has achieved statistically significant improvements in primary endpoints in Phase II and Phase III double-blind, randomized, placebo-controlled clinical trials with a generally well tolerated safety profile and supported by open-label trials in the United States and Europe."<ref name="Mitchell, 2016"/> *2017, Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy<ref>Glen J. Weiss, Julia Beck, Donald P. Braun, Kristen Bornemann-Kolatzki, Heather Barilla, Rhiannon Cubello, Walter Quan Jr, Ashish Sangal, Vivek Khemka, Jordan Waypa, William M. Mitchell, Howard Urnovitz and Ekkehard Schütz; Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy; Clin Cancer Res; 23(17); 5074-81. doi:10.1158/1078-0432.CCR-17-0231</ref>
Summary:
Please make sure your edits are consistent with
MEpedia's guidelines
.
By saving changes, you agree to the
Terms of use
, and you irrevocably agree to release your contribution under the
CC BY-SA 3.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)
Navigation
Navigation
Skip to content
Main page
Browse
Become an editor
Random page
Popular pages
Abbreviations
Glossary
About MEpedia
Links for editors
Contents
Guidelines
Recent changes
Pages in need
Search
Help
Wiki tools
Wiki tools
Special pages
Page tools
Page tools
User page tools
More
What links here
Related changes
Page information
Page logs